Skip to main content
Clinical Trials/NCT03642158
NCT03642158
Completed
Not Applicable

Targeted Transcranial Magnetic Stimulation for Cognitive Rehabilitation After Traumatic Brain Injury

Hunter Holmes Mcguire Veteran Affairs Medical Center1 site in 1 country34 target enrollmentDecember 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cognitive Impairment
Sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Enrollment
34
Locations
1
Primary Endpoint
Auditory target detection task
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

A novel and promising therapy for cognitive dysfunction is non-invasive brain stimulation, of which transcranial magnetic stimulation (TMS) is a form. TMS is currently FDA-approved for use in depression and migraine. It is under investigation for use in a number of other neurologic and psychiatric disorders. In addition to its potential to improve affective symptoms, recent research has suggested that TMS targeted to select cortical regions can also improve cognition. In trials of TMS therapy for psychiatric disorders, several studies have shown benefits for cognitive function alongside symptom amelioration. In healthy persons, a course of stimulation of the parietal area improved objective measures of learning and memory. Among persons with TBI, there have been case reports supporting improvement in cognitive function and postconcussive symptoms; however, there have not yet been any controlled studies of TMS for TBI-related cognitive dysfunction.

Detailed Description

Subjects with a history of TBI will be recruited into this double-blind, sham controlled, crossover with washout study design. Study will involve one week (5 consecutive days) of treatment, a 7 day off period, followed by a second week of rTMS treatment. Motor threshold will determine level of stimulation, and active rTMS stimulation will occur of the right DLPFC. Subjects will be paid for their time.

Registry
clinicaltrials.gov
Start Date
December 1, 2017
End Date
November 30, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Responsible Party
Principal Investigator
Principal Investigator

George Gitchel

Director of Clinical Research, Parksinon's Disease Education, Research and Clinical Center (PADRECC)

Hunter Holmes Mcguire Veteran Affairs Medical Center

Eligibility Criteria

Inclusion Criteria

  • one or more mild to moderate TBIs\*;
  • at least one year but no more than 20 years from worst injury;
  • ability to complete cognitive and neurophysiological testing;
  • available for duration of study;
  • between 18 and 65 years of age;
  • mild or greater cognitive symptoms on the TBI-QOL Cognition General Concerns scale

Exclusion Criteria

  • severe or penetrating TBI;
  • history of psychotic or manic illness;
  • history of intracranial surgery;
  • history of skull fracture;
  • history of seizures in candidate or candidate's family
  • ferrous metallic implants or implantable medical device;
  • medications that are known to reduce seizure threshold;
  • history of multiple sclerosis, stroke, brain tumor, epilepsy

Outcomes

Primary Outcomes

Auditory target detection task

Time Frame: 10 minutes

subjects listen to a series of sounds, and will monitor for a specific sounds.

California Verbal Learning Test II

Time Frame: 10 minutes

subjects are required to learn and recall an unfamiliar word list.

DKEFS Verbal Fluency

Time Frame: 10 minutes

a measure of internal search and selection process, requires subject to generate several lists of items.

Ruffs 2 and 7 selective attention test

Time Frame: ~5 minutes

subjects must visually search for the numbers 2 and 7 among other distractors.

Secondary Outcomes

  • EEG(10 minutes)

Study Sites (1)

Loading locations...

Similar Trials